Oncohematología y Genética

Terapias Avanzadas y Biomarcadores en Sarcomas (TERABIS)

Javier Martín Broto
Javier Martín Broto
IBiS
Campus Hospital Universitario Virgen del Rocío
Avda. Manuel Siurot, s/n.
41013 · Sevilla
Laboratorio: 215

Javier Martín Broto

Volver al programa
  1. Miembros del grupo
  2. Áreas de trabajo
  3. Publicaciones

Grupo: Terapias Avanzadas y Biomarcadores en Sarcomas (TERABIS)

Directorio
Miembros del grupo Terapias Avanzadas y Biomarcadores en Sarcomas (TERABIS)
  • Acosta López, María José.Lda. en Biología
  • Amián Ruíz, Rubén.Ldo. en Biotecnología
  • Blanco Alcaina, Elena.Becaria GEIS
  • Carrasco García, Irene.MIR HUVR
  • da Silva Moura, David.Doctor en Ciencias Biológicas
  • Gavilán Naranjo, Angela María.Técnico de Apoyo. Doctora en Biotecnología
  • Hidalgo Ríos, Samuel.MIR HUVR
  • Hindi Muñiz, Nadia.Facultativo Especialista de Área. Investigadora Predoctoral.
  • Lacerenza, Serena.Doctora en Bioquímica y Biología Molecular
  • López Álvarez, María.Investigadora en Formación
  • Martín Broto , Javier.Dr. en Biomedicina. Adjunto de la Unidad de Oncología Médica. Hospital Universitario Virgen del Rocío.
  • Mondaza Hernández, José Lucinio.Investigador en formación. PFIS.
  • Sánchez Bustos, Paloma.Investigadora Predoctoral.
  • Santos Fernández, Paloma.Grado en Medicina. MIR. Estudiante de Doctorado.

Áreas de trabajo

El laboratorio de Terapias Avanzadas y Biomarcadores en Sarcomas (TERABIS; IR: Javier Martín Broto), conforma un equipo traslacional y pre-clínico integrado por oncólogos especializados en la clínica de sarcomas del Hospital Virgen del Rocío de Sevilla (Centro de Referencia Nacional y Europeo) y biólogos moleculares.

 Los objetivos principales del grupo son:

  • Probar nuevas combinaciones de fármacos en sarcomas
  • Identificar nuevas dianas terapéuticas en sarcomas
  • Identificar factores pronósticos y predictivos de respuesta a tratamiento en sarcomas.

 Para ello, el grupo diseña y participa en nuevos ensayos clínicos y pre-clínicos,  colaborando con entidades públicas y privadas, a nivel nacional e internacional.

 Al mismo tiempo, cuenta con modernas instalaciones para desarrollar sus propios estudios traslacionales, usando técnicas de biología  molecular y de análisis genómicos. Actualmente, nuestros esfuerzos preclínicos se centran en tres tipos de estudios principales:

           La realización de estudios genómicos basados en hibridaciones con microarrays y secuenciación de nueva generación (NGS) para identificar patrones moleculares relevantes para el desarrollo o tratamiento de los sarcomas.

-          El establecimiento de modelos in vitro con la creación de líneas celulares de sarcomasresistentes a fármacos.

-          El desarrollo de modelos PDX de ratón para estudiar, in vivo, .

 El laboratorio cuenta con financiación pública y privada en proyectos de investigación y lidera redes de trabajo y consorcios nacionales e internacionales (SELNET; H2020; https://selnet-h2020.org/).

 

MISION:

  • Dar racional para el desarrollo de ensayos clínicos mediante;
  • La exploración de nuevas combinaciones farmacológicas en sarcomas;
  • La Identificación de nuevas dianas terapéuticas relevantes en sarcoma;
  • Formación y docencia;
  • Publicación y presentaciones a congresos;
  • Tesis doctorales, trabajos fin de máster, trabajo fin de grado;
  • Aplicación a proyectos de investigación competitiva: regional, nacional e internacional;
  • Generar modelos PDX y nuevas líneas células;
  • Identifica factores pronósticos y predictivos de respuesta en sarcoma;
  • Nuevas técnicas;
  • Desarrollar proyectos de investigación clínica y traslacional independientes;
  • Trabajo en red.

  VISION:

  • Posibilitar nuevos fármacos o mejoras en sarcomas;
  • Mejorar la calidad de vida en pacientes;
  • Mejorar la supervivencia;
  • Mejorar la estratificación molecular pronostica y predictiva;
  • Optimizar la secuencia terapéutica;
  • Sostenibilidad financiera del grupo;
  • Mejorar como grupo y red;
  • Foco en sarcoma;
  • Estrategia;
  • Establecer redes de trabajo.

 VALORES:

  • Ética profesional;
  • Autocrítica;
  • Compromiso/esfuerzo;
  • Solidaridad/compañerismo;
  • Reciprocidad;
  • Generosidad;
  • Entusiasmo e ilusión;
  • Empatía.

 

 

 

Revistas Internacionales
Tap, WD; Wagner, AJ; Schoffski, P; Martin-Broto, J; Krarup-Hansen, A; Ganjoo, KN; Yen, CC; Razak, AAR; Spira, A; Kawai, A; Le Cesne, A; Van Tine, BA; Naito, Y; Park, SH; Fedenko, A; Papai, Z; Soldatenkova, V; Shahir, A; Mo, G; Wright, J; Jones, RL
Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas The ANNOUNCE Randomized Clinical Trial
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Martin-Broto, J; Hindi, N; Lopez-Pousa, A; Peinado-Serrano, J; Alvarez, R; Alvarez-Gonzalez, A; Italiano, A; Sargos, P; Cruz-Jurado, J; Isern-Verdum, J; Dolado, MC; Rincon-Perez, I; Sanchez-Bustos, P; Gutierrez, A; Romagosa, C; Morosi, C; Grignani, G; Gatti, M; Luna, P; Alastuey, I; Redondo, A; Belinchon, B; Martinez-Serra, J; Sunyach, MP; Coindre, JM; Dei Tos, AP; Romero, J; Gronchi, A; Blay, JY; Moura, DS
Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas A Nonrandomized Phase 1/2 Clinical Trial
JAMA ONCOLOGY
D'Ambrosio, L; Touati, N; Blay, JY; Grignani, G; Flippot, R; Czarnecka, AM; Piperno-Neumann, S; Martin-Broto, J; Sanfilippo, R; Katz, D; Duffaud, F; Vincenzi, B; Stark, DP; Mazzeo, F; Tuchscherer, A; Chevreau, C; Sherriff, J; Estival, A; Litiere, S; Sents, W; Ray-Coquard, I; Tolomeo, F; Le Cesne, A; Rutkowski, P; Stacchiotti, S; Kasper, B; Gelderblom, H; Gronchi, A
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
CANCER
Demetri, GD; Antonescu, CR; Bjerkehagen, B; Bovee, JVMG; Boye, K; Chacon, M; Dei Tos, AP; Desai, J; Fletcher, JA; Gelderblom, H; George, S; Gronchi, A; Haas, RL; Hindi, N; Hohenberger, P; Joensuu, H; Jones, RL; Judson, I; Kang, YK; Kawai, A; Lazar, AJ; Le Cesne, A; Maestro, R; Maki, R; Martin, J; Patel, S; Penault-Llorca, F; Raut, CP; Rutkowski, P; Safwat, A; Sbaraglia, M; Schaefer, IM; Shen, L; Serrano, C; Schoffski, P; Stacchiotti, S; Hall, KS; Tap, WD; Thomas, DM; Trent, J; Valverde, C; van der Graaf, WTA; von Mehren, M; Wagner, A; Wardelmann, E; Naito, Y; Zalcberg, J; Blay, JY
Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network
ANNALS OF ONCOLOGY
Radaelli, S; Fossati, P; Stacchiotti, S; Akiyama, T; Asencio, JM; Bandiera, S; Boglione, A; Boland, P; Bolle, S; Bruland, O; Brunello, A; Bruzzi, P; Campanacci, D; Cananzi, F; Capanna, R; Casadei, R; Cordoba, A; Court, C; Dei Tos, AP; DeLaney, TF; De Paoli, A; De Pas, TM; Desai, A; Di Brina, L; Donati, DM; Fabbri, N; Fiore, MR; Frezza, A; Gambarotti, M; Gasbarrini, A; Georg, P; Grignani, G; Hindi, N; Hug, EB; Jones, R; Kawai, A; Krol, AD; Le Grange, F; Luzzati, A; Marquina, G; Martin-Benlloch, JA; Mazzocco, K; Navarria, F; Navarria, P; Parchi, PD; Patel, S; Pennacchioli, E; Petrongari, MG; Picci, P; Pollock, R; Porcu, L; Quagliuolo, V; Sangalli, C; Scheipl, S; Scotto, GM; Spalek, M; Steinmeier, T; Timmermann, B; Trama, A; Uhl, M; Valverde, C; Varga, PP; Verges, R; Weber, DC; Zoccali, C; Casali, PG; Sommer, J; Gronchi, A
The sacral chordoma margin
EJSO
Martin-Broto, J; Cruz, J; Penel, N; Le Cesne, A; Hindi, N; Luna, P; Moura, DS; Bernabeu, D; de Alava, E; Lopez-Guerrero, JA; Dopazo, J; Pena-Chilet, M; Gutierrez, A; Collini, P; Karanian, M; Redondo, A; Lopez-Pousa, A; Grignani, G; Diaz-Martin, J; Marcilla, D; Fernandez-Serra, A; Gonzalez-Aguilera, C; Casali, PG; Blay, JY; Stacchiotti, S
Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial
LANCET ONCOLOGY
Perez, M; Garcia-Heredia, JM; Felipe-Abrio, B; Munoz-Galvan, S; Martin-Broto, J; Carnero, A
Sarcoma stratification by combined pH2AX and MAP17 (PDZK1IP1) levels for a better outcome on doxorubicin plus olaparib treatment
SIGNAL TRANSDUCTION AND TARGETED THERAPY
Martin-Broto, J; Reichardt, P; Jones, RL; Stacchiotti, S
Different approaches to advanced soft tissue sarcomas depending on treatment line, goal of therapy and histological subtype
EXPERT REVIEW OF ANTICANCER THERAPY
Gonzalez, LMD; Martin-Broto, J; Kasper, B; Blay, JY; Le Cesne, A
Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma
EXPERT REVIEW OF ANTICANCER THERAPY
Martin-Broto, J; Moura, DS
New drugs in gastrointestinal stromal tumors
CURRENT OPINION IN ONCOLOGY
Napolitano, A; Provenzano, S; Colombo, C; Vitellaro, M; Brunello, A; Badalamenti, G; Nannini, M; Ibrahim, T; Hohenberger, P; Gasperoni, S; Gennatas, S; Jones, RL; Hindi, N; Martin-Broto, J; Ceruso, MS; Silletta, M; Tos, APD; Gronchi, A; Stacchiotti, S; Santini, D; Tonini, G; Palassini, E; Vincenzi, B
Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis
ESMO OPEN
Constantinidou, A; Sauve, N; Stacchiotti, S; Blay, JY; Vincenzi, B; Grignani, G; Rutkowski, P; Guida, M; Hindi, N; Klein, A; Thibaud, V; Sufliarsky, J; Desar, I; Steeghs, N; Litiere, S; Gelderblom, H; Jones, RL
Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study
ESMO OPEN
Martin-Broto, J; Hindi, N; Grignani, G; Martinez-Trufero, J; Redondo, A; Valverde, C; Stacchiotti, S; Lopez-Pousa, A; D'Ambrosio, L; Gutierrez, A; Perez-Vega, H; Encinas-Tobajas, V; de Alava, E; Collini, P; Pena-Chilet, M; Dopazo, J; Carrasco-Garcia, I; Lopez-Alvarez, M; Moura, DS; Lopez-Martin, JA
Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial
JOURNAL FOR IMMUNOTHERAPY OF CANCER
Martin-Broto, J; Moura, DS; Van Tine, BA
Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas
CLINICAL CANCER RESEARCH
Serrano, C; Vivancos, A; Lopez-Pousa, A; Matito, J; Mancuso, FM; Valverde, C; Quiroga, S; Landolfi, S; Castro, S; Dopazo, C; Sebio, A; Virgili, AC; Menso, MM; Martin-Broto, J; Sanso, M; Garcia-Valverde, A; Rosell, J; Fletcher, JA; George, S; Carles, J; Arribas, J
Clinical value of next generation sequencing of plasma cell-free DNA in gastrointestinal stromal tumors
BMC CANCER
Anderton, J; Moroz, V; Marec-Berard, P; Gaspar, N; Laurence, V; Martin-Broto, J; Sastre, A; Gelderblom, H; Owens, C; Kaiser, S; Fernandez-Pinto, M; Fenwick, N; Evans, A; Strauss, S; Whelan, J; Wheatley, K; Brennan, B
International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 Protocol
TRIALS
Gronchi, A; Palmerini, E; Quagliuolo, V; Broto, JM; Pousa, AL; Grignani, G; Brunello, A; Blay, JY; Tendero, O; Diaz Beveridge, R; Ferraresi, V; Lugowska, I; Merlo, DF; Fontana, V; Marchesi, E; Braglia, L; Donati, DM; Palassini, E; Bianchi, G; Marrari, A; Morosi, C; Stacchiotti, S; Bague, S; Coindre, JM; Dei Tos, AP; Picci, P; Bruzzi, P; Casali, PG
Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups
JOURNAL OF CLINICAL ONCOLOGY
Martin-Broto, J; Hindi, N; Aguiar, S; Badilla-Gonzalez, R; Castro-Oliden, V; Chacon, M; Correa-Generoso, R; de Alava, E; Donati, DM; Eriksson, M; Falla-Jimenez, M; German, G; Silva, MLG; Gouin, F; Gronchi, A; Haro-Varas, JC; Jimenez-Brenes, N; Kasper, B; de Mello, CAL; Maki, R; Martinez-Delgado, P; Martinez-Said, H; Martinez-Tlahuel, JL; Morales-Perez, JM; Munoz-Casares, FC; Nakagawa, SA; Ortiz-Cruz, EJ; Palmerini, E; Patel, S; Moura, DS; Stacchiotti, S; Sunyach, MP; Valverde, CM; Waisberg, F; Blay, JY
Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic
ONCOLOGIST
Kamposioras, K; Mauri, D; Papadimitriou, K; Anthoney, A; Hindi, N; Petricevic, B; Dambrosio, M; Valachis, A; Kountourakis, P; Kopecky, J; Kuhar, CG; Popovic, L; Chilingirova, NP; Zarkavelis, G; de Mello, RA; Plavetic, ND; Christopoulos, C; Mostert, B; Goffin, JR; Tzachanis, D; Saraireh, HH; Ma, F; Pavese, I; Tolia, M
Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth
FRONTIERS IN ONCOLOGY
Moura, DS; Sanchez-Bustos, P; Fernandez-Serra, A; Lopez-Alvarez, M; Mondaza-Hernandez, JL; Blanco-Alcaina, E; Gavilan-Naranjo, A; Martinez-Delgado, P; Lacerenza, S; Santos-Fernandez, P; Carrasco-Garcia, I; Hidalgo-Rios, S; Gutierrez, A; Ramos, R; Hindi, N; Taron, M; Lopez-Guerrero, JA; Martin-Broto, J
CUL4A, ERCC5, and ERCC1 as Predictive Factors for Trabectedin Efficacy in Advanced Soft Tissue Sarcomas (STS): A Spanish Group for Sarcoma Research (GEIS) Study
CANCERS
Martinez-Font, E; Perez-Capo, M; Ramos, R; Felipe, I; Garcias, C; Luna, P; Terrasa, J; Martin-Broto, J; Vogler, O; Alemany, R; Obrador-Hevia, A
Impact of Wnt/beta-Catenin Inhibition on Cell Proliferation through CDC25A Downregulation in Soft Tissue Sarcomas
CANCERS
Fernandez-Serra, A; Moura, DS; Sanchez-Izquierdo, MD; Calabuig-Farinas, S; Lopez-Alvarez, M; Martinez-Martinez, A; Carrasco-Garcia, I; Ramirez-Calvo, M; Blanco-Alcaina, E; Lopez-Reig, R; Obrador-Hevia, A; Alemany, R; Gutierrez, A; Hindi, N; Poveda, A; Lopez-Guerrero, JA; Martin-Broto, J
Prognostic Impact of let-7e MicroRNA and Its Target Genes in Localized High-Risk Intestinal GIST: A Spanish Group for Research on Sarcoma (GEIS) Study
CANCERS
Hindi, N; Garcia, IC; Sanchez-Camacho, A; Gutierrez, A; Peinado, J; Rincon, I; Benedetti, J; Sancho, P; Santos, P; Sanchez-Bustos, P; Marcilla, D; Encinas, V; Chacon, S; Munoz-Casares, C; Moura, D; Martin-Broto, J
Trabectedin Plus Radiotherapy for Advanced Soft-Tissue Sarcoma: Experience in Forty Patients Treated at a Sarcoma Reference Center
CANCERS
Martinez-Delgado, P; Lacerenza, S; Obrador-Hevia, A; Lopez-Alvarez, M; Mondaza-Hernandez, JL; Blanco-Alcaina, E; Sanchez-Bustos, P; Hindi, N; Moura, DS; Martin-Broto, J
Cancer Stem Cells in Soft-Tissue Sarcomas
CELLS
Stacchiotti S, Ferrari S, Redondo A, Hindi-Muniz N, Palmerini E, Vaz Salgado MA, Frezza AM, Casali PG, Gutierrez A, Lopez-Pousa A, Grignani G, Italiano A, LeCesne A, Dumont S, Blay JY, Penel N, Bernabeu D, de Alava E, Karanian M, Morosi C, Brich S, Dagrada GP, Vallacchi V, Castelli C, Brenca M, Racanelli D, Maestro R, Collini P, Cruz J, Martin-Broto J.
Pazopanib for f advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial
Lancet Oncol.
Martin-Broto J, Stacchiotti S, Lopez-Pousa A, Redondo A, Bernabeu D, de Alava E, Casali PG, Italiano A, Gutierrez A, Moura DS, Peña-Chilet M, Diaz-Martin J, Biscuola M, Taron M, Collini P, Ranchere-Vince D, Garcia Del Muro X, Grignani G, Dumont S, Martinez-Trufero J, Palmerini E, Hindi N, Sebio A, Dopazo J, Dei Tos AP, LeCesne A, Blay JY, Cruz J.
Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.
Lancet Oncol
Tap WD, Gelderblom H, Palmerini E, Desai J, Bauer S, Blay JY, Alcindor T, Ganjoo K, Martín-Broto J, Ryan CW, Thomas DM, Peterfy C, Healey JH, van de Sande M, Gelhorn HL, Shuster DE, Wang Q, Yver A, Hsu HH, Lin PS, Tong-Starksen S, Stacchiotti S, Wagner AJ, ENLIVEN investigators
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.
Lancet.
Martin-Broto J, Moura DS, Hindi N
Pazopanib in the treatment of advanced solitary fibrous tumour - Authors' reply.
Lancet Oncol.
Martin-Broto J, Stacchiotti S, Lopez-Pousa A, Redondo A, Bernabeu D, de Alava E, Casali PG, Italiano A, Gutierrez A, Moura DS, Peña-Chilet M, Diaz-Martin J, Biscuola M, Taron M, Collini P, Ranchere-Vince D, Garcia Del Muro X, Grignani G, Dumont S, Martinez-Trufero J, Palmerini E, Hindi N, Sebio A, Dopazo J, Dei Tos AP, LeCesne A, Blay JY, Cruz J
Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial.
Lancet Oncol
Stacchiotti S, Ferrari S, Redondo A, Hindi N, Palmerini E, Vaz Salgado MA, Frezza AM, Casali PG, Gutierrez A, Lopez-Pousa A, Grignani G, Italiano A, LeCesne A, Dumont S, Blay JY, Penel N, Bernabeu D, de Alava E, Karanian M, Morosi C, Brich S, Dagrada GP, Vallacchi V, Castelli C, Brenca M, Racanelli D, Maestro R, Collini P, Cruz J, Martin-Broto J
Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial.
Lancet Oncol.
Puerto-Camacho P, Amaral AT, Lamhamedi-Cherradi SE, Menegaz BA, Castillo-Ecija H, Ordóñez JL, Domínguez S, Jordan-Perez C, Diaz-Martin J, Romero-Pérez L, Lopez-Alvarez M, Civantos-Jubera G, Robles-Frías MJ, Biscuola M, Ferrer C, Mora J, Cuglievan B, Schadler K, Seifert O, Kontermann R, Pfizenmaier K, Simón L, Fabre M, Carcaboso ÁM, Ludwig JA, de Álava E
Preclinical Efficacy of Endoglin-Targeting Antibody-Drug Conjugates for the Treatment of Ewing Sarcoma.
Clin Cancer Res.
Sanfilippo R, Jones RL, Blay JY, Le Cesne A, Provenzano S, Antoniou G, Mir O, Fucà G, Fumagalli E, Bertulli R, Stacchiotti S, Brahmi M, Grosso F, Dufresne A, Hindi N, Sbaraglia M, Gronchi A, Collini P, Dei Tos AP, Casali PG
Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas).
Clin Cancer Res
Fucà G, Hindi N, Ray-Coquard I, Colia V, Dei Tos AP, Martin-Broto J, Brahmi M, Collini P, Lorusso D, Raspagliesi F, Pantaleo MA, Vincenzi B, Fumagalli E, Gronchi A, Casali PG, Sanfilippo R
Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study.
Oncologist.
Martin-Broto J, Hindi N
In Reply.
Oncologist.
Martin-Broto J, Hindi N, Cruz J, Martinez-Trufero J, Valverde C, De Sande LM, Sala A, Bellido L, De Juan A, Rubió-Casadevall J, Diaz-Beveridge R, Cubedo R, Tendero O, Salinas D, Gracia I, Ramos R, Baguè S, Gutierrez A, Duran-Moreno J, Lopez-Pousa A
Relevance of Reference Centers in Sarcoma Care and Quality Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS).
Oncologist
Serrano C, García-Del-Muro X, Valverde C, Sebio A, Durán J, Manzano A, Pajares I, Hindi N, Landolfi S, Jiménez L, Rubió-Casadevall J, Estival A, Lavernia J, Safont MJ, Pericay C, Díaz-Beveridge R, Martínez-Marín V, Vicente-Baz D, Vivancos A, Hernández-Losa J, Arribas J, Carles J .
Clinicopathological and Molecular Characterization of Metastatic Gastrointestinal Stromal Tumors with Prolonged Benefit to Frontline Imatinib.
Oncologist
Martin-Broto J, Hindi N, Moura DS
Which goals should we pursue in each line of treatment for advanced soft tissue sarcoma?
Future Oncol.
Álvarez Álvarez R, Cruz Jurado J, Del Muro Solans XG, Giner JL, López Pousa A, Martín-Broto J, Valverde CM
Optimization of the Therapeutic Approach to Patients with Sarcoma: Delphi Consensus.
Sarcoma.
Gronchi A, Hindi N, Cruz J, Blay JY, Lopez-Pousa A, Italiano A, Alvarez R, Gutierrez A, Rincón I, Sangalli C, Pérez Aguiar JL, Romero J, Morosi C, Sunyach MP, Sanfilippo R, Romagosa C, Ranchere-Vince D, Dei Tos AP, Casali PG, Martin-Broto J
Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups.
EClinicalMedicine.
Alemany R, Moura DS, Redondo A, Martinez-Trufero J, Calabuig S, Saus C, Obrador-Hevia A, Ramos R, Villar VH, Valverde C, Vaz MA, Medina J, Felipe-Abrio I, Hindi N, Taron M, Martin-Broto J.
Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma.
Clin Cancer Res.
Moura DS, Ramos R, Fernandez-Serra A, Serrano T, Cruz J, Alvarez-Alegret R, Ortiz-Duran R, Vicioso L, Gomez-Dorronsoro ML, Garcia Del Muro X, Martinez-Trufero J, Rubio-Casadevall J, Sevilla I, Lainez N, Gutierrez A, Serrano C, Lopez-Alvarez M, Hindi N, Taron M, López-Guerrero JA, Martin-Broto J.
Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients.
Oncotarget
Alemany R, Moura DS, Redondo A, Martínez-Trufero J, Calabuig S, Saus C, Obrador-Hevia A, Ramos R, Villar VH, Valverde C, Vaz MA, Medina J, Felipe-Abrio I, Hindi N, Tarón M, Martín-Broto J.
Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma
Clin Cancer Res.
Álvarez R, Carrato A, Adeva J, Alés I, Prados S, Valladares M, Macarulla T, Muñoz A, Hidalgo M.
Management of hyperbilirubinaemia in pancreatic cancer patients.
Eur J Cancer.
Blancas I, Fontanillas M, Conde V, Lao J, Martínez E, Sotelo MJ, Jaén A, Bayo JL, Carabantes F, Illarramendi JJ, Gordon MM, Cruz J, García-Palomo A, Mendiola C, Pérez-Ruiz E, Bofill JS, Baena-Cañada JM, Jáñez NM, Esquerdo G, Ruiz-Borrego M.
Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice.
Clin Transl Oncol.
Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, de Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hannu A, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, Van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY, ESMO Guidelines Committee and EURACAN.
Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol.
Casali PG, Bielack S, Abecassis N, Aro HT, Bauer S, Biagini R, Bonvalot S, Boukovinas I, Bovee JVMG, Brennan B, Brodowicz T, Broto JM, Brugières L, Buonadonna A, de Álava E, Dei Tos AP, Del Muro XG, Dileo P, Dhooge C, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gaspar N, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hassan B, Hecker-Nolting S, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kager L, Kasper B, Kopeckova K, Krákorová DA, Ladenstein R, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Morland B, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Strauss SJ, Sundby Hall K, Unk M, Van Coevorden F, van der Graaf WTA, Whelan J, Wardelmann E, Zaikova O, Blay JY, ESMO Guidelines Committee, PaedCan and ERN EURACAN.
Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol
Espinosa M, Roldán-Romero JM, Durán I, de Álava E, Apellániz-Ruiz M, Cascón A, Garrigós C, Robledo M, Rodríguez-Antona C.
Advanced sporadic renal epithelioid angiomyolipoma: case report of an extraordinary response to sirolimus linked to TSC2 mutation.
BMC Cancer.
Ferrer I, Quintanal-Villalonga Á, Molina-Pinelo S, García-Heredia JM, Pérez M, Suárez R, Ponce-Aix S, Paz-Ares L, Carnero A.
MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma.
J Exp Clin Cancer Res.
Frezza AM, Jones RL, Lo Vullo S, Asano N, Lucibello F, Ben-Ami E, Ratan R, Teterycz P, Boye K, Brahmi M, Palmerini E, Fedenko A, Vincenzi B, Brunello A, Desar IME, Benjamin RS, Blay JY, Broto JM, Casali PG, Gelderblom H, Grignani G, Gronchi A, Hall KS, Mir O, Rutkowski P, Wagner AJ, Anurova O, Collini P, Dei Tos AP, Flucke U, Hornick JL, Lobmaier I, Philippe T, Picci P, Ranchere D, Renne SL, Sbaraglia M, Thway K, Wagrodzki M, Wang WL, Yoshida A, Mariani L, Kawai A, Stacchiotti S.
Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series.
JAMA Oncol.
Fucà G, Hindi N, Ray-Coquard I, Colia V, Dei Tos AP, Martín-Broto J, Brahmi M, Collini P, Lorusso D, Raspagliesi F, Pantaleo MA, Vincenzi B, Fumagalli E, Gronchi A, Casali PG, Sanfilippo R.
Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study.
Oncologist
García Del Muro X, Maurel J, Martínez Trufero J, Lavernia J, López Pousa A, de Las Peñas R, Cubedo R, Berros JP, Casado Herráez A, de Juan A, Martín Broto J.
Phase II trial of ifosfamide in combination with the VEGFR inhibitor sorafenib in advanced soft tissue sarcoma: a Spanish group for research on sarcomas (GEIS) study
Invest New Drugs
Lindner LH, Litière S, Sleijfer S, Benson C, Italiano A, Kasper B, Messiou C, Gelderblom H, Wardelmann E, Le Cesne A, Blay JY, Marreaud S, Hindi N, Desar IME, Gronchi A, van der Graaf WTA.
Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Int J Cancer
Martín Broto J.
Advancing towards Better Cooperation for Better Sarcoma Prognoses.
Oncology
Martín-Broto J, Hindi N, Cruz J, Martínez-Trufero J, Valverde C, De Sande LM, Sala A, Bellido L, De Juan A, Rubió-Casadevall J, Díaz-Beveridge R, Cubedo R, Tendero O, Salinas D, Gracia I, Ramos R, Baguè S, Gutiérrez A, Durán-Moreno J, López-Pousa A.
Relevance of Reference Centers in Sarcoma Care and Quality Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS).
Oncologist.
Martín-Liberal J, López-Pousa A, Martínez-Trufero J, Martín-Broto J, Cubedo R, Lavernia J, Redondo A, López-Martín JA, Mulet-Margalef N, Sanjuan X, Tirado ÒM, Garcia-Del-Muro X.
Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study.
Target Oncol.
Medina-López RA, Tarón M, Osman-García I, Durán I.
Molecular biology of castration resistant prostate cancer.
Arch Esp Urol.
Moura DS, Ramos R, Fernández-Serra A, Serrano T, Cruz J, Álvarez-Alegret R, Ortiz-Durán R, Vicioso L, Gómez-Dorronsoro ML, García Del Muro X, Martínez-Trufero J, Rubio-Casadevall J, Sevilla I, Laínez N, Gutiérrez A, Serrano C, López-Álvarez M, Hindi N, Tarón M, López-Guerrero JA, Martín-Broto J.
Gene expression analyses determine two different subpopulations in KIT-negative GIST-like (KNGL) patients.
Oncotarget.
Núñez-Valdovinos B, Carmona-Bayonas A, Jiménez-Fonseca P, Capdevila J, Castaño-Pascual Á, Benavent M, Pi Barrio JJ, Teule A, Alonso V, Custodio A, Marazuela M, Segura Á, Beguiristain A, Llanos M, Martínez Del Prado MP, Díaz-Perez JA, Castellano D, Sevilla I, López C, Alonso T, García-Carbonero R.
Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Oncologist.
Pasquali S, Colombo C, Pizzamiglio S, Verderio P, Callegaro D, Stacchiotti S, Martín Broto J, López-Pousa A, Ferrari S, Poveda A, De Paoli A, Quagliuolo V, Jurado JC, Comandone A, Grignani G, De Sanctis R, Palassini E, Llomboart-Bosch A, Dei Tos AP, Casali PG, Picci P, Gronchi A.
High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial.
Eur J Cancer.
Pavel M, Gross DJ, Benavent M, Perros P, Srirajaskanthan R, Warner RRP, Kulke MH, Anthony LB, Kunz PL, Hörsch D, Weickert MO, Lapuerta P, Jiang W, Kassler-Taub K, Wason S, Fleming R, Fleming D, García-Carbonero R.
Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial
Endocr Relat Cancer.
Peeters M, Forget F, Karthaus M, Valladares-Ayerbes M, Zaniboni A, Demonty G, Guan X, Rivera F.
Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma.
ESMO open
Quintanal-Villalonga Á, Mediano M, Ferrer I, Meléndez R, Carranza-Carranza A, Suárez R, Carnero A, Molina-Pinelo S, Paz-Ares L.
Histology-dependent prognostic role of pERK and p53 protein levels in early-stage non-small cell lung cancer.
Oncotarget
Quintanal-Villalonga Á, Ojeda-Márquez L, Marrugal Á, Yagüe P, Ponce-Aix S, Salinas A, Carnero A, Ferrer I, Molina-Pinelo S, Paz-Ares L.
The FGFR4-388arg Variant Promotes Lung Cancer Progression by e Cadherin Induction.
Sci Rep.
Ray-Coquard I, Serre D, Reichardt P, Martín-Broto J, Bauer S.
Options for treating different soft tissue sarcoma subtypes.
Future Oncol.
Stacchiotti S, Mir O, Le Cesne A, Vincenzi B, Fedenko A, Maki RG, Somaiah N, Patel S, Brahmi M, Blay JY, Boye K, Sundby Hall K, Gelderblom H, Hindi N, Martín-Broto J, Kosela H, Rutkowski P, Italiano A, Duffaud F, Kobayashi E, Casali PG, Provenzano S, Kawai A.
Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma.
Oncologist.
Taieb J, Rivera F, Siena S, Karthaus M, Valladares-Ayerbes M, Gallego J, Geissler M, Koukakis R, Demonty G, Peeters M.
Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials.
J Cancer Res Clin Oncol.
Templeton AJ, Rodríguez-Lescure Á, Ruíz A, Alba E, Calvo L, Ruíz-Borrego M, Santaballa A, Rodríguez CA, Crespo C, Ramos M, Gracia-Marco JM, Lluch A, Álvarez I, Casas MI, Sánchez-Aragó M, Caballero R, Carrasco E, Amir E, Martin M, Ocaña A, GEICAM 9906 Study Investigators.
Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy.
Clin Transl Oncol.
Tena I, Gupta G, Tajahuerce M, Benavent M, Cifrián M, Falcón A, Fonfria M, Del Olmo M, Reboll R, Conde A, Moreno F, Balaguer J, Cañete A, Palasí R, Bello P, Marco A, Ponce JL, Merino JF, Llombart A, Sanchez A, Pacak K.
Successful Second-Line Metronomic Temozolomide in Metastatic Paraganglioma: Case Reports and Review of the Literature.
Clin Med Insights Oncol.
Martín-Broto J.
Theory and practice of the management of advanced dedifferentiated liposarcoma. The practice - Case 2.
Cancer Chemotherapy Reviews
Strauss SJ, Anninga J, Baglio R, Baumhoer D, Behjati S, Bielack S, Boye K, Broto JM, Cleton-Jansen AM, Degasperi A, Evans A, Fagioli F, Fiocco M, Gaspar N, Heymann D, Hindi N, Lancia C, Myklebost O, Nathrath M, Redini F, Scotlandi K, Tirtei E, Vanden Eynden M, Whelan J.
Report from the 4th European Bone Sarcoma Networking meeting: focus on osteosarcoma.
Clinical Sarcoma Research.
Martín-Broto J.
Centros de referencia en sarcomas. Perspectiva histórica y racional de su existencia.
Revisiones en Cancer
Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, de Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, Gronchi A, Haas RL, Hannu A, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, Van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY, ESMO Guidelines Committee and EURACAN.
Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ann Oncol
Martin-Broto J, Redondo A, Valverde C, Vaz MA, Mora J, Garcia Del Muro X, Gutierrez A, Tous C, Carnero A, Marcilla D, Carranza A, Sancho P, Martinez-Trufero J, Diaz-Beveridge R, Cruz J, Encinas V, Taron M, Moura DS, Luna P, Hindi N, Lopez-Pousa A.
Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS).
Ann Oncol
Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J, Loriot Y, Necchi A, Hoffman-Censits J, Pérez-Gracia JL, Dawson NA, van der Heijden MS, Dreicer R, Srinivas S, Retz MM, Joseph RW, Drakaki A, Vaishampayan UN, Sridhar SS, Quinn DI, Durán I, Shaffer DR, Eigl BJ, Grivas PD, Yu EY, Li S, Kadel EE, Boyd Z, Bourgon R, Hegde PS, Mariathasan S, Thåström A, Abidoye OO, Fine GD, Bajorin DF, IMvigor210 Study Group.
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Lancet.
. Banerjee S, Califano R, Corral J, de Azambuja E, De Mattos-Arruda L, Guarneri V, Hutka M, Jordan K, Martinelli E, Mountzios G, Ozturk MA, Petrova M, Postel-Vinay S, Preusser M, Qvortrup C, Volkov MNM, Tabernero J, Olmos D, Strijbos MH.
Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey
Ann Oncol.
Bautista F, Gallego S, Cañete A, Mora J, Díaz de Heredia C, Cruz O, Fernández JM, Rives S, Berlanga P, Hladun R, Juan Ribelles A, Madero L, Ramírez M, Fernández Delgado R, Pérez-Martínez A, Mata C, Llort A, Martín Broto J, Cela ME, Ramírez G, Sábado C, Acha T, Astigarraga I, Sastre A, Muñoz A, Guibelalde M, Moreno L, en nombre de la Sociedad Española de Oncología Pediátrica (SEHOP) y el Grupo de Nuevas Terapias en Oncología Pediátrica, Sociedad Española de Hematología y Oncología Pediátrica (SEHOP) and the New Drug Development Group in Pediatric Oncology.
Early clinical trials in paediatric oncology in Spain: a nationwide perspective
An Pediatr (Barc).
Caballero Gullón L, Carmona González E, Martínez Estévez A, Gómez Camarero MP, Corral JJ, Borrego Dorado I.
Primary squamous cell carcinoma of the thyroid. Initial assessment and follow-up using 18F-FDG PET/CT.
Rev Esp Med Nucl Imagen Mol.
Carrato A, Abad A, Massuti B, Grávalos C, Escudero P, Longo-Muñoz F, Manzano JL, Gómez A, Safont MJ, Gallego J, García-Paredes B, Pericay C, Dueñas R, Rivera F, Losa F, Valladares-Ayerbes M, González E, Aranda E, Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD).
Eur J Cancer.
Conteduca V, Wetterskog D, Sharabiani MTA, Grande E, Fernández-Pérez MP, Jayaram A, Salvi S, Castellano D, Romanel A, Lolli C, Casadio V, Gurioli G, Amadori D, Font A, Vázquez-Estévez S, González Del Alba A, Mellado B, Fernández-Calvo O, Méndez-Vidal MJ, Climent MA, Durán I, Gallardo E, Rodríguez A, Santander C, Sáez MI, Puente J, Gasi Tandefelt D, Wingate A, Dearnaley D, PREMIERE Collaborators, Spanish Oncology Genitourinary Group, Demichelis F, De Giorgi U, González-Billalabeitia E, Attard G.
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.
Ann Oncol.
Díaz-Díaz A, Casas-Pais A, Calamia V, Castosa R, Martínez-Iglesias O, Roca-Lema D, Santamarina I, Valladares-Ayerbes M, Calvo L, Chantada V, Figueroa A.
Proteomic Analysis of the E3 Ubiquitin-Ligase Hakai Highlights a Role in Plasticity of the Cytoskeleton Dynamics and in the Proteasome System.
J Proteome Res
Durán I, Fink MG, Bahl A, Hoefeler H, Mahmood A, Lüftner D, Ghazal H, Wei R, Chung KC, Hechmati G, Green J, Atchison C.
Health resource utilisation associated with skeletal-related events in patients with bone metastases secondary to solid tumours: regional comparisons in an observational study.
Eur J Cancer Care (Engl).
Durán I, Lambea J, Maroto P, González-Larriba JL, Flores L, Granados-Principal S, Graupera M, Sáez B, Vivancos A, Casanovas O.
Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.
Target Oncol.
García-Carbonero R, Salazar R, Durán I, Osman-García I, Paz-Ares L, Bozada JM, Boni V, Blanc C, Seymour L, Beadle J, Alvis S, Champion B, Calvo E, Fisher K.
Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection.
J Immunother Cancer.
Garon EB, Reck M, Paz-Ares L, Ponce S, Jaime JC, Juan O, Nadal E, Lee P, Dalal R, Liu J, He S, Treat J, Nakagawa K.
Treatment Rationale and Study Design for the RELAY Study: A Multicenter, Randomized, Double-Blind Study of Erlotinib With Ramucirumab or Placebo in Patients With Epidermal Growth Factor Receptor Mutation-Positive Metastatic Non-Small-Cell Lung Cancer.
Clin Lung Cancer.
Garrigós C, Espinosa M, Salinas A, Osman I, Medina R, Tarón M, Molina-Pinelo S, Durán I.
Single nucleotide polymorphisms as prognostic and predictive biomarkers in renal cell carcinoma.
Oncotarget.
Girard N, Corral J, Cortinovis D, Heigener DF.
Second-Line Treatment Selection in Patients With Non-Small-Cell Lung Cancer of Adenocarcinoma Histology: Findings From a European Survey of Treating Physicians.
Clin Lung Cancer.
González-Billalabeitia E, Castellano D, Sobrevilla N, Guma J, Hervás D, Luengo MI, Aparicio J, Sánchez-Muñoz A, Mellado B, Sáenz A, Valverde C, Fernández A, Margeli M, Durán I, Fernández S, Sastre J, Ros S, Maroto P, Manneh R, Cerezuela P, Carmona-Bayonas A, Ayala de la Peña F, Aguilar JL, Rivera S, García del Muro X, Germà-Lluch JR, Spanish Germ Cell Cancer Group/Grupo Germinal (SGCCG).
Prognostic Significance of Venous Thromboembolic Events in Disseminated Germ Cell Cancer Patients
J Natl Cancer Inst.
González-Cámpora R., Ramos Asensio R., Vallejo-Benítez A., Marcilla-Plaza D., Biscuola M., Martínez-Marín V., Serrano C., Hindi N., López-Guerrero J.-A., Martin-Broto J.
Tumores del estroma gastrointestinal: breve actualización y consenso de la SEAP-SEOM sobre diagnóstico patológico y molecular.
Rev Esp Patol.
González-Larriba JL, Maroto P, Durán I, Lambea J, Flores L, Castellano D, The Changing Group.
The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges.
Expert Rev Anticancer Ther.
Gronchi A, Ferrari S, Quagliuolo V, Broto JM, Pousa AL, Grignani G, Basso U, Blay JY, Tendero O, Beveridge RD, Ferraresi V, Lugowska I, Merlo DF, Fontana V, Marchesi E, Donati DM, Palassini E, Palmerini E, De Sanctis R, Morosi C, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Casali PG.
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Lancet Oncol
Joensuu H, Blay JY, Comandone A, Martín-Broto J, Fumagalli E, Grignani G, Del Muro XG, Adenis A, Valverde C, Pousa AL, Bouché O, Italiano A, Bauer S, Barone C, Weiss C, Crippa S, Camozzi M, Castellana R, Le Cesne A.
Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib.
Br J Cancer
Kasper B, Baumgarten C, García J, Bonvalot S, Haas R, Haller F, Hohenberger P, Penel N, Messiou C, van der Graaf WT, Gronchi A, Desmoid Working Group.
An update on the management of sporadic desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG).
Ann Oncol.
Kempf E, Desamericq G, Vieites B, Díaz-Padilla I, Calvo E, Estévez P, García-Arreza A, Martínez-Maestre MA, Durán I.
Clinical and pathologic features of patients with non-epithelial ovarian cancer: retrospective analysis of a single institution 15-year experience.
Clin Transl Oncol.
Koutsoukos K, Bamias A, Tzannis K, Espinosa Montaño M, Bozionelou V, Christodoulou C, Stefanou D, Kalofonos H, Durán I, Papazisis K.
Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib
Onco Targets Ther.
Maleki Vareki S, Garrigós C, Durán I.
Biomarkers of response to PD-1/PD-L1 inhibition
Crit Rev Oncol Hematol.
Martín Broto J, Le Cesne A, Reichardt P.
The importance of treating by histological subtype in advanced soft tissue sarcoma.
Future Oncol.
Martín M, Chan A, Dirix L, O'Shaughnessy J, Hegg R, Manikhas A, Shtivelband M, Krivorotko P, Batista López N, Campone M, Ruiz Borrego M, Khan QJ, Beck JT, Ramos Vázquez M, Urban P, Goteti S, Di Tomaso E, Massacesi C, Delaloge S.
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4).
Ann Oncol.
Martín M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Morán S, Yao B, Xu F, Auerbach A, Buyse M, Chan A, ExteNET Study Group.
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol.
Martín-Broto J, Martínez-Marín V, Serrano C, Hindi N, López-Guerrero JA, Bisculoa null, Ramos-Asensio R, Vallejo-Benítez A, Marcilla-Plaza D, González-Cámpora R.
Gastrointestinal stromal tumors (GISTs): SEAP-SEOM consensus on pathologic and molecular diagnosis.
Clin Transl Oncol.
Martín-Broto J, Redondo A, Valverde C, Vaz MA, Mora J, García Del Muro X, Gutiérrez A, Tous C, Carnero A, Marcilla D, Carranza A, Sancho P, Martínez-Trufero J, Díaz-Beveridge R, Cruz J, Encinas V, Tarón M, Moura DS, Luna P, Hindi N, López-Pousa A.
Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS).
Ann Oncol.
Martín-Broto J, Reichardt P, Stacchiotti S, Blay JY.
Review of past and present clinical cases with a view to future treatment options.
Future Oncol.
Martínez-Font E, Felipe-Abrio I, Calabuig-Fariñas S, Ramos R, Terrasa J, Vögler O, Alemany R, Martín-Broto J, Obrador-Hevia A.
Disruption of TCF/β-Catenin Binding Impairs Wnt Signaling and Induces Apoptosis in Soft Tissue Sarcoma Cells.
Mol Cancer Ther.
Martínez-Pérez J, López-Calderero I, Sáez C, Benavent M, Limón ML, González-Expósito R, Soldevilla B, Riesco-Martínez MC, Salamanca J, Carnero A, García-Carbonero R.
Prognostic relevance of Src activation in stage II-III colon cancer.
Hum Pathol.
Mora J, Castañeda A, Pérez-Jaume S, López-Pousa A, Maradiegue E, Valverde C, Martín-Broto J, García Del Muro X, Cruz O, Cruz J, Martínez-Trufero J, Maurel J, Vaz MA, de Álava E, de Torres C.
GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS).
Br J Cancer.
Ortiz-Prieto A., Domínguez-Cruz J., Sancho-Márquez P., Conejo-Mir J.
Vitíligo como marcador clínico de respuesta a pembrolizumab en un paciente con melanoma metastásico.
Piel
Pérez-Gracia JL, Loriot Y, Rosenberg JE, Powles T, Necchi A, Hussain SA, Morales-Barrera R, Retz MM, Niegisch G, Durán I, Théodore C, Grande E, Shen X, Wang J, Nelson B, Derleth CL, van der Heijden MS.
Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens.
Eur Urol.
Poveda A, García Del Muro X, López-Guerrero JA, Cubedo R, Martínez V, Romero I, Serrano C, Valverde C, Martín-Broto J, GEIS (Grupo Español de Investigación en Sarcomas/Spanish Group for Sarcoma Research).
GEIS guidelines for gastrointestinal sarcomas (GIST).
Cancer Treat Rev.
Quintanal-Villalonga Á, Carranza-Carranza A, Meléndez R, Ferrer I, Molina-Pinelo S, Paz-Ares L.
Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement.
Clin Lung Cancer.
Redondo A, Bagué S, Bernabeu D, Ortiz-Cruz E, Valverde C, Álvarez R, Martínez-Trufero J, López-Martín JA, Correa R, Cruz J, López-Pousa A, Santos A, García Del Muro X, Martín-Broto J.
Malignant bone tumors (other than Ewing's): clinical practice guidelines for diagnosis, treatment and follow-up by Spanish Group for Research on Sarcomas (GEIS).
Cancer Chemother Pharmacol.
Rivera F, Valladares M, Gea S, López-Martínez N.
Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
J Med Econ.
Rodríguez-Moreno JF, Apellaniz-Ruiz M, Roldán-Romero JM, Durán I, Beltrán L, Montero-Conde C, Cascón A, Robledo M, García-Donas J, Rodríguez-Antona C.
Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel MTOR-Activating Mutation.
J Natl Compr Canc Netw.
Sánchez-Gastaldo A, Kempf E, González Del Alba A, Durán I.
Systemic treatment of renal cell cancer: A comprehensive review
Cancer Treat Rev.
Stacchiotti S, Gronchi A, Fossati P, Akiyama T, Alapetite C, Baumann M, Blay JY, Bolle S, Boriani S, Bruzzi P, Capanna R, Caraceni A, Casadei R, Colia V, Debus J, Delaney T, Desai A, Dileo P, Dijkstra S, Doglietto F, Flanagan A, Froelich S, Gardner PA, Gelderblom H, Gokaslan ZL, Haas R, Heery C, Hindi N, Hohenberger P, Hornicek F, Imai R, Jeys L, Jones RL, Kasper B, Kawai A, Krengli M, Leithner A, Logowska I, Martín Broto J, Mazzatenta D, Morosi C, Nicolai P, Norum OJ, Patel S, Penel N, Picci P, Pilotti S, Radaelli S, Ricchini F, Rutkowski P, Scheipl S, Sen C, Tamborini E, Thornton KA, Timmermann B, Torri V, Tunn PU, Uhl M, Yamada Y, Weber DC, Vanel D, Varga PP, Vleggeert-Lankamp CLA, Casali PG, Sommer J.
Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group.
Ann Oncol.
Verdugo-Sivianes EM, Navas L, Molina-Pinelo S, Ferrer I, Quintanal-Villalonga A, Peinado J, García-Heredia JM, Felipe-Abrio B, Muñoz-Galván S, Marín JJ, Montuenga L, Paz-Ares L, Carnero A.
Coordinated downregulation of Spinophilin and the catalytic subunits of PP1, PPP1CA/B/C, contributes to a worse prognosis in lung cancer.
Oncotarget
Wehler T, Thomas M, Schumann C, Bosch-Barrera J, Viñolas Segarra N, Dickgreber NJ, Dalhoff K, Sebastián M, Corral Jaime J, Alonso M, Hynes SM, Lin J, Hurt K, Bence Lin A, Calvo E, Paz-Ares L.
A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer.
Lung Cancer.
Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS.
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Lancet Oncol.
Robles C, Conde M, Beneditti J, Medina R, Sancho P, Congregado B, Osman I, Durán I.
Desperation Surgery as a Successful Approach in Chemorefractory Testicular Germ Cell Cancer: The Relevance of a Multidisciplinary Approach.
JSM Clin Oncol Res.
Martin-Broto J, Pousa AL, de Las Peñas R, García Del Muro X, Gutierrez A, Martinez-Trufero J, Cruz J, Alvarez R, Cubedo R, Redondo A, Maurel J, Carrasco JA, López-Martin JA, Sala Á, Meana JA, Ramos R, Martinez-Serra J, Lopez-Guerrero JA, Sevilla I, Balaña C, Vaz Á, De Juan A, Alemany R, Poveda A.J
Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study.
J Clin Oncol